Cost effectiveness and budget impact of universal varicella vaccination in Russia

• Auteurs principaux: Alen Marijam (Auteur), Ekaterina Safonova (Auteur), Mikhail Scherbakov (Auteur), Evgeniy Shpeer (Auteur), Desirée Van Oorschot (Auteur), Alla Rudakova (Auteur), Vladimir Tatochenko (Auteur), Nikolay Briko (Auteur)
• Format: Livre
• Publié: Taylor & Francis Group, 2022-11-01T00:00:00Z.
• Sujets: article
• Accès en ligne: Connect to this object online.
• Notes: 2164-5515; 2164-554X; 10.1080/21645515.2022.2045152
• Keywords: budget impact; cost-effectiveness; economic evaluation; childhood vaccination; varicella; russian federation; chickenpox; Immunologic diseases. Allergy; RC581-607; Therapeutics. Pharmacology; RM1-950
• Source: Human Vaccines & Immunotherapeutics, Vol 18, Iss 5 (2022)

This economic evaluation assesses the cost-effectiveness and budget impact of introducing a two-dose varicella vaccine in the Russian national immunization program. A static Markov model followed a simulated 2019 Russian cohort over its lifetime and compared outcomes and costs of three varicella vaccination strategies: strategy I (doses given at 12 and 15 months of age), strategy II (doses given at 1 year and 6 years of age), and a no vaccination scenario. Inputs on age-dependent clinical pathways, associated costs, and related health outcomes were collected from national sources and published literature. Results are presented as incremental cost-effectiveness ratio (ICER) from the healthcare payer and societal perspective over the lifetime of the birth cohort and the budget impact over a 10 years' time horizon. Vaccination strategies I and II resulted in an ICER of approximately 1.7 million rubles per quality-adjusted life years gained from the healthcare payer perspective and were cost-saving from the societal perspective. From the healthcare payer perspective, the costs per varicella case averted were 5,989 and 7,140 rubles per case for strategies I and II, respectively. However, from the societal perspective, vaccination is a dominant strategy and the budget impact analysis shows significant healthcare savings over 10 years, with strategy I realizing savings of ~2 billion rubles more than strategy II. From a public health impact perspective, varicella vaccination of children at 12 and 15 months of age through the Russian NIP is expected to be cost-effective with an affordable budget impact compared to no vaccination.